Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Castiglione-Gertsch M, Price KN, Coates AS, Smith I, Viale G, Rabaglio M,<br />
Zabaznyi N, Goldhirsch A 2007 Predictors of early relapse in postmenopausal<br />
women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann<br />
Oncol 18:859-67<br />
116. Dowsett M 2004 Biomarker investigations from the ATAC trial: the role of<br />
TA01. 27th San Antonio Breast Cancer Symposium; Breast Cancer Res Treat<br />
2004; 88 Suppl 1: S11<br />
117. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller<br />
WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M 2001<br />
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for<br />
ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:<br />
evidence from a phase III randomized trial. J Clin Oncol 19:3808-16<br />
118. Zhu L, Chow LW, Loo WT, Guan XY, Toi M 2004 Her2/neu expression<br />
predicts the response to antiaromatase neoadjuvant therapy in primary breast<br />
cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin<br />
Cancer Res 10:4639-44<br />
119. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J,<br />
Detre S, Hills M, Walsh G 2007 Prognostic value of Ki67 expression after short-<br />
term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst<br />
99:167-70<br />
120. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter<br />
J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE 2005 Biomarker<br />
changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence<br />
58
Change language